The Ultimate Velvet Rope

On genomics, longevity, and who gets to know first.

Lauren Berkowitz · May 26, 2026

Everyone has noticed, and everyone has a theory. The commentary runs across social media in a permanent loop: red light therapy, peptides, NAD infusions, methylene blue, cold plunges, rapamycin, berberine, continuous glucose monitors, sleep tracking, mouth taping, infrared saunas, grounding mats, beef tallow, seed oil elimination, and about 40 other things cycling through feeds daily, each with its own passionate constituency and its own before and after. A whole layer of people, not just the names everyone knows but the executives, the partners, the senior people adjacent to serious wealth, look noticeably different than they did 10 years ago, more energy, visibly healthier, younger in a way that reads as systemic rather than cosmetic, and the internet is running a permanent open investigation into why.

I have an expanded take. The most consequential advantage may not be the intervention everyone can see. It may be the information most people still do not have.

Earlier this month, Mayo Clinic drew attention to a study published this spring that received little mainstream attention. Researchers used whole-genome sequencing in 484 seemingly healthy people and found that 1 in 8 carried a medically actionable genetic finding they did not know about, involving risks such as hereditary breast and ovarian cancer, Lynch syndrome, cardiomyopathy, long QT syndrome and amyloidosis, findings that routine care would not typically have uncovered. It received little pickup, possibly because 484 people is a small cohort and the 1 in 8 finding is higher than estimates from larger population studies. But even the conservative estimate is enormous. Before I use the 1/8 to do some math, some context:

A 2023 synthesis by Eric Topol of large population studies across the US and Iceland found roughly 1 in 25 people carrying actionable findings they didn't know about, using stricter gene lists and much larger sample sizes than Mayo used. That figure is more statistically robust than what Mayo found in 484 people, whose cohort was drawn from biobank volunteers, which may limit how broadly its prevalence estimate can be generalized. These are real limitations and I'm not dismissing them.

The reason I believe the direction of the Mayo number anyway is what is happening to the category itself. The American College of Medical Genetics and Genomics first published a list in 2013 of 56 genes for which certain unexpected findings identified during clinical sequencing should be reported back to patients because action could be taken.

That secondary findings list is now at 84 genes and continues to be updated. Its expansion does not prove that Mayo's 13 percent estimate applies across the general population, but it points in the same direction: the category of medically actionable genomic information is still growing. On top of that, variants currently sitting in a gray zone may be reclassified as more data accumulates, with computational tools increasingly helping researchers interpret them. There are also categories of risk not counted in these figures, including the cumulative effect of hundreds of common variants that individually mean little but together may matter significantly. And genomic datasets have historically overrepresented people of European ancestry, leaving important gaps in what can be interpreted accurately across populations. The field is not approaching a final answer, every year it finds more.

So take the 1 in 8. In a company of 1,000 employees, that is roughly 125 people walking around with a genetic risk they could act on and do not know about. In a family reunion of 40, that is 5. On a sports team with a 25-person roster, 3. The number is not exotic. It is sitting in every room you walk into, including the ones you are in.

Here is where it gets uncomfortable. The people most likely to already know this information about themselves are the people with the resources to go looking for it. Whole-genome sequencing, sophisticated interpretation, the specialists who can turn a variant into a plan, all of it currently sits behind a price and an access barrier that sorts by wealth. The knowledge gap is not evenly distributed, and it is compounding.

This is the velvet rope. Not a supplement stack or a cold plunge, but early access to a true reading of your own biology, and the head start that comes with acting on it before symptoms, before diagnosis, before it is too late to change the trajectory. Longevity has been framed as a matter of discipline and money, the ability to construct a perfect lifestyle. The deeper divide is informational. It is the difference between the people who know what is coming and the people who find out when it arrives.

The optimistic case is that this information follows the path of every other technology, expensive and exclusive at first, then rapidly cheaper and more accessible. Sequencing cost has already collapsed from millions to a few hundred dollars. The interpretation layer is where the current bottleneck sits, and it is exactly the kind of problem that AI is positioned to compress. There is a version of the near future where a true reading of your biology costs less than a phone and comes with guidance a specialist would have charged thousands for a decade ago.

But cost coming down is not the same as access arriving. Someone has to build the layer that translates raw genomic data into something a person can act on, at consumer scale, without a concierge budget. That layer does not fully exist yet. The science is moving faster than the infrastructure to deliver it, and in the gap, the advantage accrues to whoever can already afford the human version.

There is also a real argument for caution. Not everyone wants to know. A positive result for a condition you can't do anything about is a different weight to carry than a result that comes with a clear preventive path. Genetic information can create anxiety, complicate insurance, and burden people with knowledge they didn't ask for and can't unlearn. The right to not know is real, and any honest version of this conversation has to hold it alongside the case for access.

But the population where knowing changes the outcome is large and growing. For hereditary breast and ovarian cancer, for Lynch syndrome, for the cardiac conditions on that list, early knowledge is not a burden, it is the whole game. It is the difference between surveillance and surprise, between a preventive step and a late diagnosis. For those people, and there are millions of them, the information is not a luxury. It is the highest-leverage medical fact about their lives, and most of them do not have it.

The velvet rope is not going to fall on its own. Sequencing getting cheaper solves the easy half. The hard half is the interpretation and guidance layer, the thing that turns data into decisions, built for everyone rather than for the people who can already buy the human version. Whoever builds that decides whether this becomes the tool that closes the gap or the one that widens it. Right now, the rope is still up, and the line on the other side is longer than most people realize.

The question that stays with me is not whether this information is powerful. It clearly is. The question is who gets to stand on which side of the rope, and for how long, and whether the people building the future of this decide to let the rope down on purpose, or leave it up because up is where the advantage lives.